Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to -$305.2 million.

  • Revolution Medicines' Net Income towards Common Stockholders fell 9528.43% to -$305.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$961.0 million, marking a year-over-year decrease of 6946.64%. This contributed to the annual value of -$600.1 million for FY2024, which is 3752.03% down from last year.
  • Revolution Medicines' Net Income towards Common Stockholders amounted to -$305.2 million in Q3 2025, which was down 9528.43% from -$247.8 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Net Income towards Common Stockholders peaked at -$37.2 million during Q1 2021, and registered a low of -$305.2 million during Q3 2025.
  • For the 5-year period, Revolution Medicines' Net Income towards Common Stockholders averaged around -$117.8 million, with its median value being -$98.3 million (2023).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 727.28% in 2022, then crashed by 18587.08% in 2023.
  • Quarter analysis of 5 years shows Revolution Medicines' Net Income towards Common Stockholders stood at -$52.7 million in 2021, then decreased by 7.27% to -$56.5 million in 2022, then tumbled by 185.87% to -$161.5 million in 2023, then dropped by 20.45% to -$194.6 million in 2024, then tumbled by 56.86% to -$305.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$305.2 million for Q3 2025, versus -$247.8 million for Q2 2025 and -$213.4 million for Q1 2025.